Pharmacoeconomic review report. Letermovir (Prevymis) (Merck Canada Inc.).
Letermovir is an antiviral agent that can be administered orally or intravenously at a dosage of 480 mg daily (or 240 mg daily if co-administered with cyclosporine A) in patients undergoing an allogeneic hematopoietic stem cell transplant (HSCT) as prophylaxis of cytomegalovirus (CMV) infection. The...
Saved in:
| Online Access: |
Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
CADTH,
2018
|
| Edition: | Final pharmacoeconomic review report (with redactions). |
| Series: | Common drug review clinical review report.
|
| Subjects: |
| Summary: | Letermovir is an antiviral agent that can be administered orally or intravenously at a dosage of 480 mg daily (or 240 mg daily if co-administered with cyclosporine A) in patients undergoing an allogeneic hematopoietic stem cell transplant (HSCT) as prophylaxis of cytomegalovirus (CMV) infection. The recommended treatment regimen, as per the Health Canada-approved product monograph, is initiation of letermovir on the day of HSCT or up to 28 days post-transplant and continued through 100 days post-HSCT. At the manufacturer's submitted price ($251.28 for the oral formulations and the 240 mg intravenous [IV] vial, $493.78 for the 480 mg IV vial), the average daily drug cost ranges from $251.28 to $493.78. The average cost per treatment, assuming a treatment course of 100 days, ranges from $25,128 to $49,378 per patient. The manufacturer submitted a cost-utility analysis comparing letermovir as prophylaxis of CMV infection, taken alongside usual care, in adult (50.8 years old) CMV-seropositive HSCT recipients compared with usual care alone. |
|---|---|
| Physical Description: | 1 online resource (1 PDF file (42 pages)) : illustrations. |
| Bibliography: | Includes bibliographical references. |
| Source of Description, Etc. Note: | Description based on online resource; title from PDF title page (viewed July 12, 2019). |
| Funding Information Note: | Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec. |
